Reply to: Does Total Neoadjuvant Treatment Improve Overall Survival in Rectal Cancer? No, It Does Not

Joseph C Kong^{1

2}, Sam Ngan^{3

4}, Jeanne Tie^{3

5}, Alexander G Heriot^{6

3}

Affiliations

¹ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. joekong@gmail.com.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia. joekong@gmail.com.
³ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
⁴ Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
⁵ Division of Radiation Oncology, Peter MacCallum Cancer Centre,, Melbourne, VIC, Australia.
⁶ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Comment

Joseph C Kong et al. Ann Surg Oncol. 2021 Dec.

. 2021 Dec;28(Suppl 3):795-796.

doi: 10.1245/s10434-021-10434-y. Epub 2021 Jul 17.

Joseph C Kong^{1

2}, Sam Ngan^{3

4}, Jeanne Tie^{3

5}, Alexander G Heriot^{6

3}

¹ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. joekong@gmail.com.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia. joekong@gmail.com.
³ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
⁴ Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
⁵ Division of Radiation Oncology, Peter MacCallum Cancer Centre,, Melbourne, VIC, Australia.
⁶ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

No abstract available

Comment on

Does Total Neoadjuvant Treatment Improve Overall Survival in Rectal Cancer? No, It Does Not.
Socha J, Bujko K. Socha J, et al. Ann Surg Oncol. 2021 Dec;28(Suppl 3):797-800. doi: 10.1245/s10434-021-10432-0. Epub 2021 Jul 14. Ann Surg Oncol. 2021. PMID: 34258722 No abstract available.

1. Kong JC, Soucisse M, Michael M, et al. Total neoadjuvant therapy in locally advanced rectal cancer: a systematic review and metaanalysis of oncological and operative outcomes. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-09837-8 .
1. Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–15. - DOI
1. Garant A, Kavan P, Martin AG, et al. Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: the KIR randomized phase II trial. Radiother Oncol. 2021;155:237–45. - DOI
1. Fokas E, Allgäuer M, Polat B, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37:3212–22. - DOI
1. Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42. - DOI